The Effect of Biologic and Targeted Synthetic Drugs on Work- and Productivity-related Outcomes for Patients with Psoriatic Arthritis: A Systematic Review

REFERENCES

1. 1.↵
   1. Chandran V,
   2. Raychaudhuri SP

   . Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:J314–21.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Bojke L,
   2. Spackman E,
   3. Hinde S,
   4. Helliwell P

   . Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatology 2012;51:210–5.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Olivieri I,
   2. D’Angelo S,
   3. Palazzi C,
   4. Padula A

   . Challenges in economic evaluation of psoriatic arthritis. J Rheumatol 2010;37:1086–8.

   OpenUrlFREE Full Text
4. 4.↵
   1. Zhu TY,
   2. Tam LS,
   3. Leung YY,
   4. Kwok LW,
   5. Wong KC,
   6. Yu T,
   7. et al.

   Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 2010;37:1214–20.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Tillett W,
   2. de-Vries C,
   3. McHugh NJ

   . Work disability in psoriatic arthritis: a systematic review. Rheumatology 2012;51:275–83.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Kawalec P,
   2. Malinowski KP

   . The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2015;15:125–32.

   OpenUrl
7. 7.↵
   1. Mease PJ

   . Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am 2015;41:723–38.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Lee S,
   2. Mendelsohn A,
   3. Sarnes E

   . The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 2010;35:680–9.

   OpenUrlPubMed
9. 9.↵
   1. Higgins J,
   2. Altman D,
   3. Sterne J

   . Assessing risk of bias in included studies. In: Cochrane handbook for systematic reviews of interventions. [Internet. Accessed February 16, 2018.]. The Cochrane Collaboration; 2011. Available from: handbook-5-1.cochrane.org
10. 10.↵
    1. Kavanaugh A,
    2. Antoni C,
    3. Mease P,
    4. Gladman D,
    5. Yan S,
    6. Bala M,
    7. et al.

    Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254–9.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Kavanaugh A,
    2. Gladman D,
    3. Mease P,
    4. McInnes I,
    5. Beutler A,
    6. Zrubek J,
    7. et al.

    Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week health-related quality of life, physical function and health economic results of the randomized, placebo-controlled GO-REVEAL Study. Arthritis Rheum 2009;60 Suppl:1261.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Kavanaugh A,
    2. McInnes I,
    3. Gottlieb A,
    4. Puig L,
    5. Rahman P,
    6. Ritchlin C,
    7. et al.

    Ustekinumab improves arthritis-related and skin-related quality of life in patients with active psoriatic arthritis: patient reported outcomes from randomized and double blinded phase III PSUMMIT I trial. Arthritis Rheum 2012;64 Suppl 10:S248.

    OpenUrl
13. 13.↵
    1. Kavanaugh A,
    2. Gladman D,
    3. van der Heijde D,
    4. Purcaru O,
    5. Mease P

    . Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis 2015;74:44–51.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Zhang F,
    2. Tencer T,
    3. Li S

    . SAT0392 Work productivity improvement associated with apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial. Ann Rheum Dis 2014;73:736.

    OpenUrl
15. 15.↵
    1. Rahman P,
    2. Strand V,
    3. McInnes IB,
    4. Marzo-Ortega H,
    5. Dokoupilová E,
    6. Churchill M,
    7. et al.

    THU0433 Secukinumab improves physical function, quality of life, fatigue and work productivity in patients with active psoriatic arthritis in future 2, a phase 3 trial. Ann Rheum Dis 2015;74:356.

    OpenUrl
16. 16.↵
    1. Fransen J,
    2. Stucki G,
    3. van Riel PLCM

    . Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 2003;49:S214–24.

    OpenUrlCrossRef
17. 17.↵
    1. Schmitt J,
    2. Wozel G

    . The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;11;210:194–9.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Gossec L,
    2. Smolen JS,
    3. Ramiro S,
    4. de Wit M,
    5. Cutolo M,
    6. Dougados M,
    7. et al.

    European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. van Vilsteren M,
    2. Boot CR,
    3. Knol DL,
    4. van Schaardenburg D,
    5. Voskuyl AE,
    6. Steenbeek R,
    7. et al.

    Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord 2015;16:107.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Rodgers M,
    2. Epstein D,
    3. Bojke L,
    4. Yang H,
    5. Craig D,
    6. Fonseca T,
    7. et al.

    Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15:1–329.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Cawson MR,
    2. Mitchell SA,
    3. Knight C,
    4. Wildey H,
    5. Spurden D,
    6. Bird A,
    7. et al.

    Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord 2014;15:26.

    OpenUrlPubMed
22. 22.↵
    1. Bravo Vergel Y,
    2. Hawkins NS,
    3. Claxton K,
    4. Asseburg C,
    5. Palmer S,
    6. Woolacott N,
    7. et al.

    The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 2007;46:1729–35.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Mattke S,
    2. Balakrishnan A,
    3. Bergamo G,
    4. Newberry SJ

    . A review of methods to measure health-related productivity loss. Am J Manag Care 2007;13:211–7.

    OpenUrlPubMed
24. 24.↵
    1. Sculpher M

    . The role and estimation of productivity costs. In: Economic evaluation in health care. New York: Oxford University Press; 2001:94–112.